ALPHAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
ALPHAGAN by AbbVie is alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension. First approved in 1996.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALPHAGAN (brimonidine tartrate) is an alpha-2 adrenergic receptor agonist ophthalmic solution approved in 1996 for reducing elevated intraocular pressure in open-angle glaucoma and ocular hypertension. It works through a dual mechanism: reducing aqueous humor production and increasing uveoscleral outflow, with peak effect at two hours post-dosing.
LOE Approaching
As LOE approaches, the ALPHAGAN brand team faces defensive positioning and likely consolidation; roles will prioritize retention and generic transition planning over growth initiatives.
Mechanism of Action
alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Worked on ALPHAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.